Ordering Information

LENGTH (mm)	DIAMETER (mm)							
	1.50	2.00	2.25	2.50	2.75	3.00	3.50	4.00
10	DBCA0001	DBCA0002	DBCA0003	DBCA0004	DBCA0005	DBCA0006	DBCA0007	DBCA0008
15	DBCA0009	DBCA0010	DBCA0011	DBCA0012	DBCA0013	DBCA0014	DBCA0015	DBCA0016
20	DBCA0017	DBCA0018	DBCA0019	DBCA0020	DBCA0021	DBCA0022	DBCA0023	DBCA0024
25	DBCA0025	DBCA0026	DBCA0027	DBCA0028	DBCA0029	DBCA0030	DBCA0031	DBCA0032
30		DBCA0033	DBCA0034	DBCA0035	DBCA0036	DBCA0037	DBCA0038	DBCA0039
35		DBCA0040	DBCA0041	DBCA0042	DBCA0043	DBCA0044	DBCA0045	DBCA0046
40		DBCA0047	DBCA0048	DBCA0049	DBCA0050	DBCA0051	DBCA0052	DBCA0053

Balloon design

- Length: from 10 to 40 mm
- Diameter: from 1.50 to 4.00 mm
- Nominal pressure: 6 atm
- Rated burst pressure: 16 atm
- Drug: Paclitaxel
- Excipient: BTHC
- Dose per mm^2: 2.5 µg
- Guidewire compatibility: 0.014″
- Guiding catheter compatibility:
  5F for Ø 1.50 to 3.00
  6F for Ø 3.50 to 4.00
  7F for Ø 4.00 length 30, 35 & 40 mm

Instructions for use

Predilatation recommanded with a conventional balloon.

To avoid damage to the coating:
- No handling of the balloon before insertion.
- No inflation before the Danubio is at the lesion site.

Before inserting Danubio: pre-wet the balloon in a saline solution for 10-15 seconds.

BDAN_EN_Rev1

MINVASYS

7, rue du Fossé Blanc
92230 Gennevilliers - FRANCE
Tel : +33 (0)1 47 90 70 30
Fax : +33 (0)1 47 91 05 85
info@minvasys.com - www.minvasys.com

CE 0459

Danubio

Drug Eluting Balloon

The **30**-second efficient technology

SpeedPax Technology

MINVASYS

Danubio

A **30-second** inflation is enough.



SpeedPax Technology

Paclitaxel & BTHC excipient combination ensuring an optimal drug transfer after **one 30-second balloon inflation time.**

Homogenous and consistent coating thanks to a special folding and micropipette deposition of **2.5 µg of drug per mm².**



Complete range of products to adapt to all types of lesions and vessels, even the smallest.

A quick release for a long lasting efficiency

Clinical Trials

DEBREST Trial 6 months results* - 40 patients (ISR lesions)	
In-stent Late Lumen Loss, mm	0.16±0.37
In-segment Late Lumen Loss, mm	0.18±0.56
TLR, n (%)	2 (5.0)
MACE, n (%)	2 (5.0)

DEBSIDE Trial 6 months results* - 50 patients (SB bifurcation lesions)	
Late Lumen Loss in SB, mm	-0.04±0.34
TLR in SB, n (%)	1 (2.0)
MACE, n (%)	5 (10.0)

*Data on file.

Therapeutic indications

In-Stent Restenosis (ISR).

De novo lesions in small vessel range starting at Ø1.5 mm.

Bifurcated lesions - treatment of choice for the side branch after treatment of the main branch with Nile® Pax Paclitaxel Elution